Denali Therapeutics Inc (DNLI) — Capital Reinvestment Ratio
Denali Therapeutics Inc (DNLI) has a Capital Reinvestment Ratio of 0.00x as of December 2020, meaning it reinvests 0% of its operating cash flow ($513.91 Million) in capital expenditures ($1.19 Million). Check Denali Therapeutics Inc (DNLI) tangible net worth to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Denali Therapeutics Inc Capital Reinvestment Ratio (2018–2020)
This chart tracks Denali Therapeutics Inc's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see DNLI cash flow conversion.
Annual Capital Reinvestment Ratio for Denali Therapeutics Inc (2018–2020)
Year-by-year Capital Reinvestment Ratio for Denali Therapeutics Inc from 2018 to 2020. See Denali Therapeutics Inc (DNLI) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2020 | 0.01x | $416.15 Million | $3.10 Million | ▼ -89.0% |
| 2018 | 0.07x | $50.12 Million | $3.39 Million | — |